Reduction in the total brain metastases volume in patients with EGFR-mutant non–small cell lung cancer (NSCLC) following rapid, high, and uniform brain exposure of oral [11C]osimertinib was observed in the phase 1 ODIN-BM study (NCT03463525), results of which were reported during the 2020 World Conference on Lung Cancer Singapore.
Regarding [11C]osimertinib uptake, uniform brain distribution was recorded in all patients at all 3 time points with PET exams after intravenous (IV) microdose administration (n = 4). MRI also illustrated reductions in total brain metastases volume (range, 55%-95%) after 3 to 4 weeks of treatment with oral osimertinib (Tagrisso). T1-weighted MRI scans also illustrated tumor reductions after 35 days of treatment with oral osimertinib in 1 patient.
“These data support uniform brain distribution of osimertinib in patients with NSCLC and brain metastases,”…
